Cytena, a BICO group company (Nasdaq Stockholm: BICO) and a leading provider of high-precision instruments for handling biological cells, has entered a collaboration agreement with ExcellGene SA, a leading biologics CDMO that manufactures recombinant proteins. Together, the companies will streamline cell line development workflows for highly-efficient monoclonal antibody (mAb) and complex therapeutic protein manufacturing which enables important improvements to the development workflows of the biopharmaceutical industry.
As part of the collaboration, ExcellGene is providing its high-performance CHOExpress system, a proven, high-yield mammalian host cell line for large-scale manufacturing of therapeutic proteins. Cytena will establish workflows on the new C.STATION– a next generation automated workstation for Cell Line Development. First C.STATIONs will be installed at Cytena’s biopharmaceutical customers within the next months and delivering already improved workflows with the C.STATION will lead to an even higher demand for this fully automated solution in therapeutic protein manufacturing.
“I am thrilled to announce this exciting collaboration,” said Dr. Julian Riba, CEO of Cytena. “This will allow us to establish more efficient protocols for stable CHO Cell Line Development (CLD) on our new platform. And it brings us one step further in our mission to make the production of biotherapeutic proteins faster, safer, and more affordable.”
Fully automated cell line development (CLD) from cloning single cells to the selection of high-producing clones for upscaling, has long been a goal of Contract Development & Manufacturing Organizations (CDMO) like ExcellGene. Cytena now offers a next-generation CLD platform for reducing timelines, eliminating contamination and improving cell viability in all-in-one intuitive workstation.
Prof. Florian Wurm, CSO and Co-founder of ExcellGene, states: “Having worked with several Cytena cell handling tools from the earliest days of their offerings, we were pleased to see innovative and well thought-through instrumentation, including a flow of innovative concepts aiming at addressing a major bottleneck in the development of biologics using cultivated animal cells: the proof of monoclonality.”
Dr. Stéphanie Anchisi, Head of Cell Line Development and senior scientist at ExcellGene added: “We have generated thousands of clonal cell lines using Cytena’s technology and found it very reliable, providing both single-cell isolation and image-based proof of monoclonality”.
Dr. Florian Wurm continued “Dr. Maria Wurm, CEO of ExcellGene, and I hold a deeply reflected view on the issue of monoclonality, related to the very nature of CHO cell substrates, as indicated in some of our publications. We fully respect regulatory requirements and constraints, and in our view the new C.STATION promises to be among the most suitable and regulatory-friendly products in the market today. We are happy to provide Cytena access to our high yielding CHOExpress derived pools and clonal cell populations for optimization of protocols in efficient use of the new line of instrumentation, and thus we wish to solidify our lead in science-based cell line and process development for our clients.”
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1